黄葵胶囊联合缬沙坦治疗高血压病早期肾损害临床效果

Clinical Effects of Ambrette Capsules Combined with Valsartan in Treatment of Early Renal Damage in Patients with Hypertension

目的探讨黄葵胶囊联合缬沙坦治疗高血压病早期肾损害的临床效果。方法选取2013年1月—2016年12月我院收治的高血压病伴早期肾损害96例作为研究对象,按入院顺序分为对照组和观察组,每组各48例。两组均予常规治疗,同时口服缬沙坦80 mg/d,观察组在此基础上口服黄葵胶囊5粒/次、3/d。治疗1个月后监测血压、血肌酐(Scr)、尿素(BUN)、血清胱抑素(Cys-C)、24 h尿蛋白及超氧化物歧化酶(SOD)水平变化,观察临床疗效,记录不良反应发生情况。结果与本组治疗前比较,两组治疗后血压、Scr、BUN、Cys-C及24 h尿蛋白水平降低,SOD水平升高,差异均有统计学意义(P<0.05);与对照组比较,观察组治疗后血压、Scr、BUN、Cys-C及24 h尿蛋白水平明显降低,SOD水平明显升高,差异均有统计学意义(P<0.05)。观察组总有效率(95.83%)明显高于对照组(79.17%),差异有统计学意义(P<0.05)。两组不良反应发生率比较差异无统计学意义(P>0.05)。结论黄葵胶囊联合缬沙坦对高血压病早期肾损害患者的肾功能有一定保护作用,可作为临床治疗该病的首选治疗方案。

Objective To investigate clinical effects of Ambrette Capsules combined with Valsartan in treatment of early renal damage in patients with hypertension. Methods A total of hypertension 96 patients with early renal damage admitted during January 2013 and December 2016 were divided into control group and observation group（ n = 48 for each group）according to their admission order. All patients were treated with conventional therapy and 80 mg/d Valsartan orally. Observation group was added with Ambrette Capsule（ 5 capsules/time,3/d） on this basis treatment. Levels of blood pressure,serum creatinine（ Scr）,urea（ BUN）,serum cystatin（ Cys-C）,24 h urinary protein and superoxide dismutase（ SOD） changes were detected after 1 month of treatment,and clinical effects were observed,and incidence rates of adverse reactions were also recorded in two groups. Results Compared with those before treatment,blood pressure,Scr,BUN,Cys-C and 24 h urinary protein levels were significantly decreased,while SOD levels were significantly increased after treatment in the same group in two groups（ P〈0. 05）. Compared with those in control group,blood pressure,Scr,BUN,Cys-C and 24 h urinary protein levels were significantly decreased,while SOD level was significantly increased after treatment in observation group（ P〈0. 05）. The total effective rate in observation group（ 95. 83%） was significantly higher than 79. 17% in control group（ P〈0. 05）. There was no significant difference in incidence rate of adverse reactions between the two groups（ P〈0. 05）. Conclusion Ambrette Capsules combined with Valsartan has a certain protective effect on renal function in hypertension patients with early renal damage,and therefore it can be used as the first choice for clinical treatment.